Incretin & metabolic research compounds
GLP-1 (Glucagon-Like Peptide-1)
Also known as glucagon-like peptide-1 · GLP-1(7-36) amide
The native 30-amino-acid incretin hormone from intestinal L-cells that every GLP-1 receptor agonist imitates.
In 60 seconds
Endogenous hormone and research reference; long-acting analogues (semaglutide, liraglutide, dulaglutide, tirzepatide) are approved medicines. Native GLP-1 is too short-lived for therapeutic use; class effects of its analogues are gastrointestinal first.
- A foundational review of GLP-1 production from proglucagon and its physiological actions.
- Reviews GLP-1’s glucose-dependent insulin stimulation and wider metabolic effects.
- Reviews central GLP-1 signalling in satiety and gastric motility.
Mechanism
GLP-1 is cut from proglucagon in gut L-cells and some brainstem neurons. It stimulates glucose-dependent insulin release, suppresses glucagon, slows gastric emptying and signals satiety centrally, but DPP-4 degrades it within minutes — the problem the drug class was engineered to solve.
Research status
Endogenous hormone and research reference; long-acting analogues (semaglutide, liraglutide, dulaglutide, tirzepatide) are approved medicines.
Key studies
A foundational review of GLP-1 production from proglucagon and its physiological actions.
The physiology of glucagon-like peptide 1 — Physiol Rev, 2007 · PMID 17928588
Reviews GLP-1’s glucose-dependent insulin stimulation and wider metabolic effects.
Glucagon-like peptide 1 (GLP-1) — Mol Metab, 2019 · PMID 31767182
Reviews central GLP-1 signalling in satiety and gastric motility.
Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics — Br J Pharmacol, 2022 · PMID 34519026
Reviews GLP-1’s cardiovascular biology.
The Cardiovascular Biology of Glucagon-like Peptide-1 — Cell Metab, 2016 · PMID 27345422
Safety signals in the literature
Native GLP-1 is too short-lived for therapeutic use; class effects of its analogues are gastrointestinal first.
Legal status (South Africa)
Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
Related compounds we stock
Not stocked yet — get notified
Tell us you want GLP-1 (Glucagon-Like Peptide-1) and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add GLP-1 (Glucagon-Like Peptide-1)
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is GLP-1 (Glucagon-Like Peptide-1)?
The native 30-amino-acid incretin hormone from intestinal L-cells that every GLP-1 receptor agonist imitates. GLP-1 is cut from proglucagon in gut L-cells and some brainstem neurons. It stimulates glucose-dependent insulin release, suppresses glucagon, slows gastric emptying and signals satiety centrally, but DPP-4 degrades it within minutes — the problem the drug class was engineered to solve.
What is the research status of GLP-1 (Glucagon-Like Peptide-1)?
Endogenous hormone and research reference; long-acting analogues (semaglutide, liraglutide, dulaglutide, tirzepatide) are approved medicines.
What safety signals are reported for GLP-1 (Glucagon-Like Peptide-1)?
Native GLP-1 is too short-lived for therapeutic use; class effects of its analogues are gastrointestinal first.
Does Living Water Labs stock GLP-1 (Glucagon-Like Peptide-1)?
Not at present. GLP-1 (Glucagon-Like Peptide-1) is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
More in Incretin & metabolic
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
